IP Library Granted Patent US 7,572,904
Granted Patent B2
US 7,572,904 · App. 10/811,508 · Granted Aug 11, 2009

Nucleic acids encoding respiratory syncytial virus subgroup B strain 9320

Assignee: MedImmune, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,572,904
App. No.
10/811,508
Granted
Aug 11, 2009
Kind
B2
Abstract

The complete polynucleotide sequence of the human respiratory syncytial virus subgroup B strain 9320 genome is provided. Proteins encoded by this polynucleotide sequence are also provided. Isolated or recombinant RSV (e.g., attenuated recombinant RSV), nucleic acids, and polypeptides, e.g., comprising mutations in the attachment protein G, are also provided, as are immunogenic compositions comprising such isolated or recombinant RSV, nucleic acids, and polypeptides. Related methods are also described.

Claims (19)

1. An isolated or recombinant nucleic acid comprising at least one artificially mutated nucleotide relative to SEQ ID NO: 1 or the complementary polynucleotide sequence thereof, wherein the mutated nucleotide comprises one or more of: a deleted nucleotide, an inserted nucleotide, or a substituted nucleotide, and wherein the nucleic acid comprises:

(a) a polynucleotide sequence that is greater than 97.8% identical to SEQ ID NO: 1 or the complementary polynucleotide sequence thereof, as determined by Nucleotide-Nucleotide Basic Local Alignment Search Tool (BLASTN) using default parameters, wherein the polynucleotide sequence encodes an infectious, replicating respiratory syncytial virus (RSV); or

(b) a polynucleotide sequence encoding an amino acid sequence or unique subsequence selected from the group consisting of (i) an amino acid sequence that is greater than 99.5% identical to SEQ ID NO: 9, and (ii) an amino acid sequence that is greater than 96.4% identical to SEQ ID NO: 10, as determined by BLASTP using default parameters, wherein an RSV that comprises the amino acid sequence is infectious and replicating.

2. The nucleic acid of claim 1 , wherein the nucleic acid is selected from the group consisting of a DNA, a cDNA, an RNA, and an artificial nucleic acid.

3. The nucleic acid of claim 1 , wherein the polynucleotide sequence of (a) is at least 98.5% identical to SEQ ID NO: 1 or the complementary polynucleotide sequence thereof, as determined by BLASTN using default parameters.

4. The nucleic acid of claim 1 , wherein at least one polypeptide encoded by the nucleic acid comprises at least one deleted, inserted, or substituted amino acid residue.

5. The nucleic acid of claim 4 , wherein the polypeptide comprises at least one substituted amino acid residue wherein the substitution is a substitution of a first amino acid with a second amino acid wherein the first amino acid and the second amino acid are both within the same one of the following groups of amino acids: (i) Alanine, Serine, and Threonine; (ii) Aspartic acid and Glutamic acid; (iii) Asparagine and Glutamine; (iv) Arginine and Lysine; (v) Isoleucine, Leucine, Methionine, and Valine; or (vi) Phenylalanine, Tyrosine, and Tryptophan.

6. The nucleic acid of claim 1 , wherein the at least one artificially mutated nucleotide is located in the open reading frame encoding the polypeptide of SEQ ID NO: 12.

7. The nucleic acid of claim 1 , wherein the open reading frame encoding the polypeptide of SEQ ID NO: 12 is deleted, or wherein the open reading frame encoding the polypeptide of SEQ ID NO:10 is deleted.

8. The nucleic acid of claim 6 , wherein the at least one artificially mutated nucleotide comprises a deletion, and wherein the nucleotides encoding amino acid residues 164-197 of SEQ ID NO: 12 are deleted.

9. The nucleic acid of claim 1 , wherein the at least one artificially mutated nucleotide is located in the open reading frame encoding the polypeptide of SEQ IDNO: 10.

10. The nucleic acid of claim 9 , wherein at least one of the nucleotides encoding amino acid residue 1, amino acid residue 4, amino acid residue 10, or a combination thereof, of SEQ ID NO: 10 is mutated.

11. The nucleic acid of claim 1 , wherein the unique polynucleotide subsequence of (b) comprises at least one complete open reading frame which encodes a polypeptide selected from the group consisting of SEQ ID NOs:9 and 10; or comprising a plurality of complete open reading frames.

12. An isolated or recombinant nucleic acid comprising at least one artificially mutated nucleotide relative to SEQ ID NO: 1, wherein the mutated nucleotide comprises one or more of: a deleted nucleotide, an inserted nucleotide, or a substituted nucleotide, and wherein the nucleic acid comprises at least one unique polynucleotide subsequence comprising at least 500 contiguous nucleotides of SEQ ID NO: 1 or the complementary polynucleotide sequence thereof.

13. The nucleic acid of claim 12 wherein the nucleic acid comprises at least one unique polynucleotide subsequence comprising at least 1000 contiguous nucleotides of SEQ ID NO: 1.

14. The nucleic acid of claim 12 , wherein the nucleic acid further comprises at least one polynucleotide subsequence from a different strain of virus, at least one polynucleotide subsequence from a different strain of human RSV, or at least one polynucleotide subsequence from a different species of virus.

15. The isolated or recombinant nucleic acid of claim 1 , wherein the isolated or recombinant nucleic acid comprises a polynucleotide sequence encoding an amino acid sequence that is greater than 99.5% identical to SEQ ID NO: 9.

16. The isolated or recombinant nucleic acid of claim 15 , wherein the amino acid sequence is the amino acid sequence of SEQ ID NO: 9.

17. The nucleic acid of claim 12 wherein the unique polynucleotide subsequence encodes at least 50 contiguous amino acid residues of SEQ ID NO: 10.

Assignments (3)
CHANGE OF NAME Recorded Jan 12, 2012
From: MEDIMMUNE VACCINES, INC.
To: MEDIMMUNE, INC.
Reel/Frame 027522/0436 →
CHANGE OF NAME Recorded Jan 12, 2012
From: MEDIMMUNE, INC.
To: MEDIMMUNE, LLC
Reel/Frame 027522/0608 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2004
From: CHENG, XING; PARK, HYUN JUNG; JIN, HONG
To: MEDIMMUNE VACCINES, INC.
Reel/Frame 015531/0874 →
Continuity (3)
Provisional Application 6045833100 · Mar 28, 2003
Provisional Application 6050832000 · Oct 3, 2003
Related Publication 20040224309A1 · Nov 11, 2004